Avatrombopag - Dova Pharmaceuticals

Drug Profile

Avatrombopag - Dova Pharmaceuticals

Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; E-5501; YM-477

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals
  • Class Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Thrombocytopenia
  • Phase III Idiopathic thrombocytopenic purpura

Most Recent Events

  • 27 Nov 2017 FDA assigns PDUFA action date of 21/05/2018 for avatrombopag for Thrombocytopenia in patients with chronic liver disease
  • 27 Nov 2017 The US FDA accepts NDA filing for avatrombopag for Thrombocytopenia with Priority Review
  • 03 Nov 2017 Dova Pharmaceuticals plans a phase III trial for Thrombocytopenia in February 2018 (NCT03326843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top